NIH halts clinical trial of hydroxychloroquine

A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has been stopped by the National Institutes of Health. A data and safety monitoring board (DSMB) met late Friday and determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19. After its fourth interim analysis the DSMB, which regularly monitors the trial, recommended to the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, to stop the study. NHLBI halted the trial immediately.

The trial stoppage is followed closely by the US Food and Drug Administration withdrawing the Emergency Use Authorization for hydroxychloroquine and the Oxford RECOVERY trail also halting their trial of the drug.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Skip to toolbar